Matthias Barton

Matthias Barton

Auto-generated profile, based on publicly available information

Matthias Barton

Molecular Internal Medicine, University of Zürich, Switzerland (M.B.).

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 August 2011 in Nature Reviews Endocrinology
Verified
Journal Article
Closed access
PDF file
Eric R. ProssnitzEric R. Prossnitz
Eric R. Prossnitz
MBMatthias Barton
Matthias Barton

1 May 2014 in Molecular and Cellular Endocrinology
Verified
Journal Article
Closed access
Eric R. ProssnitzEric R. Prossnitz
Eric R. Prossnitz
MBMatthias Barton
Matthias Barton

13 February 2009 in Circulation Research
Verified
Journal Article
Closed access
PDF file
EHElvira Haas
Elvira Haas
IBIndranil Bhattacharya
Indranil Bhattacharya
EBEugen Brailoiu
Eugen Brailoiu
MDMarlen Damjanović
Marlen Damjanović
GBG. Cristina Brailoiu
G. Cristina Brailoiu
MBMatthias Barton
Matthias Barton
We found that the selective stimulation of the intracellular, transmembrane G protein–coupled estrogen receptor (GPER), also known as GPR30, acutely lowers blood pressure after infusion in normotensive rats and dilates both rodent and human arterial blood vessels. Stimulation of GPER blocks vasoconstrictor-induced changes in intracellular calcium concentrations and vascular tone, as well as serum-stimulated cell proliferation of human vascular smooth muscle cells. Deletion of the GPER gene in mice abrogates vascular effects of GPER activation and is associated with visceral obesity. These findings suggest novel roles for GPER in protecting from cardiovascular disease and obesity.

24 December 2010 in Acta Physiologica
Verified
Journal Article
Closed access
PDF file
MMM. R. Meyer
M. R. Meyer
DCD. J. Clegg
D. J. Clegg
Eric R. ProssnitzEric R. Prossnitz
Eric R. Prossnitz
MBM. Barton
M. Barton

24 November 1998 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
MBMatthias Barton
Matthias Barton
CHChristian C. Haudenschild
Christian C. Haudenschild
LDLivius V. D’uscio
Livius V. D’uscio
SSSidney Shaw
Sidney Shaw
KMKlaus Münter
Klaus Münter
TLThomas F. Lüscher
Thomas F. Lüscher
This study investigated whether endothelin-1 (ET-1), a potent vasoconstrictor, which also stimulates cell proliferation, contributes to endothelial dysfunction and atherosclerosis. Apolipoprotein E (apoE)-deficient mice and C57BL/6 control mice were treated with a Western-type diet to accelerate atherosclerosis with or without ET A receptor antagonist LU135252 (50 mg/kg/d) for 30 wk. Systolic blood pressure, plasma lipid profile, and plasma nitrate levels were determined. In the aorta, NO-mediated endothelium-dependent relaxation, atheroma formation, ET receptor-binding capacity, and vascular ET-1 protein content were assessed. In apoE-deficient but not C57BL/6 mice, severe atherosclerosis developed within 30 wk. Aortic ET-1 protein content ( P < 0.0001) and binding capacity for ET A receptors was increased as compared with C57BL/6 mice. In contrast, NO-mediated, endothelium-dependent relaxation to acetylcholine (56 ± 3 vs. 99 ± 2%, P < 0.0001) and plasma nitrate were reduced (57.9 ± 4 vs. 93 ± 10 μmol/liter, P < 0.01). Treatment with the ET A receptor antagonist LU135252 for 30 wk had no effect on the lipid profile or systolic blood pressure in apoE-deficient mice, but increased NO-mediated endothelium-dependent relaxation (from 56 ± 3 to 93 ± 2%, P < 0.0001 vs. untreated) as well as circulating nitrate levels (from 57.9 ± 4 to 80 ± 8.3 μmol/liter, P < 0.05). Chronic ET A receptor blockade reduced elevated tissue ET-1 levels comparable with those found in C57BL/6 mice and inhibited atherosclerosis in the aorta by 31% without affecting plaque morphology or ET receptor-binding capacity. Thus, chronic ET A receptor blockade normalizes NO-mediated endothelial dysfunction and reduces atheroma formation independent of plasma cholesterol and blood pressure in a mouse model of human atherosclerosis. ET A receptor blockade may have therapeutic potential in patients with atherosclerosis.

1 November 2014 in Kidney International
Verified
Journal Article
Open access
PDF file
DKDONALD E Kohan
DONALD E Kohan
MBMatthias Barton
Matthias Barton
The incidence and prevalence of chronic kidney disease (CKD), with diabetes and hypertension accounting for the majority of cases, is on the rise, with up to 160 million individuals worldwide predicted to be affected by 2020. Given that current treatment options, primarily targeted at the renin-angiotensin system, only modestly slow down progression to end-stage renal disease, the urgent need for additional effective therapeutics is evident. Endothelin-1 (ET-1), largely through activation of endothelin A receptors, has been strongly implicated in renal cell injury, proteinuria, inflammation, and fibrosis leading to CKD. Endothelin receptor antagonists (ERAs) have been demonstrated to ameliorate or even reverse renal injury and/or fibrosis in experimental models of CKD, whereas clinical trials indicate a substantial antiproteinuric effect of ERAs in diabetic and nondiabetic CKD patients even on top of maximal renin-angiotensin system blockade. This review summarizes the role of ET in CKD pathogenesis and discusses the potential therapeutic benefit of targeting the ET system in CKD, with attention to the risks and benefits of such an approach.